article thumbnail

STAT+: Pharmalittle: FDA approves Pfizer’s RSV vaccine for newborns; Boehringer sues over IRA

STAT

The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60. Continue to STAT+ to read the full story…

Vaccines 236
article thumbnail

STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign

STAT

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. Sanders (I-Vt.)

Diabetes 327
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top 20 global biopharma companies report 9.6 per cent market cap growth in Q1 2024: GlobalData

Express Pharma

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. billion in 2024, according to GlobalData’s Drugs Database Pharma Intelligence Center.

article thumbnail

Downturn for top biopharma companies Q3 market cap as Covid-19 vaccine demand falls

Pharmaceutical Technology

This downturn in market cap was attributed to a decline in the demand for Covid-19 vaccines and therapies. The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. billion for Q3, according to GlobalData’s Drugs Database. trillion in Q2 2022 to $3.14

article thumbnail

STAT+: Pharmalittle: Next big hope for Alzheimer’s might not help most Black patients; drugmakers ask Supreme Court to toss terrorism-support ruling

STAT

Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us.

article thumbnail

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Pharmaceutical Technology

increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2%

article thumbnail

Transparency, social change can help pharma regain the public’s trust

pharmaphorum

The reputation of COVID-19 vaccine makers understandably soared early on, as clinical trials were started and completed in record time, giving hopes to millions of people in lockdown. Among individuals not vaccinated by choice, internet searches ranked as the number one source. Working on a diabetes drug?